<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1179">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01824446</url>
  </required_header>
  <id_info>
    <org_study_id>SPD602-109</org_study_id>
    <nct_id>NCT01824446</nct_id>
  </id_info>
  <brief_title>AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184</brief_title>
  <official_title>A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]SSP-004184 Following a Single Oral Dose in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate how the body absorbs, metabolizes (breaks down) and excretes (eliminates) the
      study drug. Further, the study will determine how much of the study drug gets into the
      bloodstream and how long it takes the body to get rid of it when given as a single dose to
      healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Half-Life (T1/2) of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time it takes for the blood plasma concentration of a substance to halve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Body Clearance (CL/F) of Radio-Labelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rate at which a drug is removed from the body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution (Vz/F) of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The distribution of a medication between plasma and the rest of the body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0→∞ Whole Blood Total Radioactivity of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Whole Blood Total Radioactivity of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax Whole Blood Total Radioactivity of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-Life Whole Blood Total Radioactivity of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F Whole Blood Total Radioactivity of Radio-Labelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F Whole Blood Total Radioactivity of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0→∞ Plasma Total Radioactivity of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Plasma Total Radioactivity of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax Plasma Total Radioactivity of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-Life Plasma Total Radioactivity of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F Plasma Total Radioactivity of Radio-Labelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F Plasma Total Radioactivity of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Total Radioactivity Excreted in Urine of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Total Radioactivity Excreted in Stool of Radiolabelled SSP-004184</measure>
    <time_frame>Up to 288 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Radiolabeled SPD602</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiolabeled SPD602 (FBS0701, SSP-004184)</intervention_name>
    <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
    <arm_group_label>Radiolabeled SPD602</arm_group_label>
    <other_name>SPD602</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male subjects aged between 18 and 65 years inclusive

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2013</firstreceived_date>
  <firstreceived_results_date>April 11, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>[14C]SSP-004184</title>
          <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>[14C]SSP-004184</title>
          <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.2" spread="3.76"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>UNITED STATES</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled SSP-004184</title>
        <description>AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Pharmacokinetic Analysis Set (PAS) was defined as all subjects in the Safety Analysis Set (SAS) for whom the primary pharmacokinetic data are considered sufficient and interpretable. The SAS consisted of subjects who received at least 1 dose of investigational product and had at least 1 post-dose safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled SSP-004184</title>
            <description>AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.</description>
            <units>ng*hr/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="251438.3" spread="59522.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Radiolabelled SSP-004184</title>
        <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maximum Plasma Concentration (Cmax) of Radiolabelled SSP-004184</title>
            <description>Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.</description>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="119000.0" spread="35014.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of Radiolabelled SSP-004184</title>
        <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Maximum Plasma Concentration (Tmax) of Radiolabelled SSP-004184</title>
            <description>Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.</description>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Half-Life (T1/2) of Radiolabelled SSP-004184</title>
        <description>The time it takes for the blood plasma concentration of a substance to halve.</description>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Plasma Half-Life (T1/2) of Radiolabelled SSP-004184</title>
            <description>The time it takes for the blood plasma concentration of a substance to halve.</description>
            <units>hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13.039" spread="5.061"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Body Clearance (CL/F) of Radio-Labelled SSP-004184</title>
        <description>The rate at which a drug is removed from the body.</description>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Body Clearance (CL/F) of Radio-Labelled SSP-004184</title>
            <description>The rate at which a drug is removed from the body.</description>
            <units>L/hr</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12.754" spread="4.251"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution (Vz/F) of Radiolabelled SSP-004184</title>
        <description>The distribution of a medication between plasma and the rest of the body.</description>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Volume of Distribution (Vz/F) of Radiolabelled SSP-004184</title>
            <description>The distribution of a medication between plasma and the rest of the body.</description>
            <units>Liters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="216.534" spread="57.590"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0→∞ Whole Blood Total Radioactivity of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC 0→∞ Whole Blood Total Radioactivity of Radiolabelled SSP-004184</title>
            <units>ng equivalents*hr/g</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="156702.7" spread="18867.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax Whole Blood Total Radioactivity of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax Whole Blood Total Radioactivity of Radiolabelled SSP-004184</title>
            <units>ng equivalents/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="57216.7" spread="15434.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax Whole Blood Total Radioactivity of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax Whole Blood Total Radioactivity of Radiolabelled SSP-004184</title>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="1.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-Life Whole Blood Total Radioactivity of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Half-Life Whole Blood Total Radioactivity of Radiolabelled SSP-004184</title>
            <units>hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.863" spread="1.687"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F Whole Blood Total Radioactivity of Radio-Labelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>CL/F Whole Blood Total Radioactivity of Radio-Labelled SSP-004184</title>
            <units>L/hr</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19.396" spread="2.623"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vz/F Whole Blood Total Radioactivity of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Vz/F Whole Blood Total Radioactivity of Radiolabelled SSP-004184</title>
            <units>Liters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="76.731" spread="39.114"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC 0→∞ Plasma Total Radioactivity of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC 0→∞ Plasma Total Radioactivity of Radiolabelled SSP-004184</title>
            <units>ng equivalents*hr/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="293626.3" spread="78627.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax Plasma Total Radioactivity of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax Plasma Total Radioactivity of Radiolabelled SSP-004184</title>
            <units>ng equivalents/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="103650.0" spread="29083.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax Plasma Total Radioactivity of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax Plasma Total Radioactivity of Radiolabelled SSP-004184</title>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="1.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-Life Plasma Total Radioactivity of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Half-Life Plasma Total Radioactivity of Radiolabelled SSP-004184</title>
            <units>hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9.389" spread="3.538"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CL/F Plasma Total Radioactivity of Radio-Labelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>CL/F Plasma Total Radioactivity of Radio-Labelled SSP-004184</title>
            <units>L/hr</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11.071" spread="3.947"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vz/F Plasma Total Radioactivity of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Vz/F Plasma Total Radioactivity of Radiolabelled SSP-004184</title>
            <units>Liters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137.108" spread="23.637"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Total Radioactivity Excreted in Urine of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Total Radioactivity Excreted in Urine of Radiolabelled SSP-004184</title>
            <units>percentage of radioactivity</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="62.4" spread="14.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Total Radioactivity Excreted in Stool of Radiolabelled SSP-004184</title>
        <time_frame>Up to 288 hours post-dose</time_frame>
        <safety_issue>No</safety_issue>
        <population>PAS</population>
        <group_list>
          <group group_id="O1">
            <title>[14C]SSP-004184</title>
            <description>A single oral dose of 3g of radio-labelled SSP-004184 on Day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Total Radioactivity Excreted in Stool of Radiolabelled SSP-004184</title>
            <units>percentage of radioactivity</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="29.9" spread="13.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>[14C]SSP-004184</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire Development LLC</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
